Photodynamic therapy of subfoveal choroidal neovascularization in pathologic myopia with verteporfin: 1-year results of a randomized clinical trial—VIP report no. 1

Photodynamic therapy of subfoveal choroidal neovascularization in pathologic myopia with verteporfin: 1-year results of a randomized clinical trial—VIP report no. 1

To determine if photodynamic therapy with verteporfin (Visudyne; CIBA Vision Corp, Duluth, GA) can improve the chance of stabilizing or improving vision (

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Ophthalmology (Rochester, Minn.) Minn.), 2001-05, Vol.108 (5), p.841-852
Hauptverfasser: Verteporfin in Photodynamic Therapy (VIP) Study Group, Verteporfin in Photodynamic Therapy Study Group
Format: Artikel
Sprache:eng
Schlagworte:
Adult
Aged
Biological and medical sciences
Choroidal Neovascularization - drug therapy
Choroidal Neovascularization - etiology
Contrast Sensitivity
Double-Blind Method
Female
Fluorescein Angiography
Follow-Up Studies
Fovea Centralis
Humans
Infusions, Intravenous
Male
Medical sciences
Middle Aged
Myopia - complications
Ophthalmology
Photochemotherapy
Photosensitizing Agents - therapeutic use
Porphyrins - therapeutic use
Retinopathies
Safety
Treatment Outcome
Verteporfin
Visual Acuity
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:To determine if photodynamic therapy with verteporfin (Visudyne; CIBA Vision Corp, Duluth, GA) can improve the chance of stabilizing or improving vision (
ISSN:0161-6420
1549-4713
DOI:10.1016/S0161-6420(01)00544-9